media – Page 630 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53%

Novartis today announced results from a Phase III study of 870 patients with stage III BRAF V600E/K mutation-positive melanoma after complete surgical resection treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) .
- Source: Novartis
- 825
- September 13, 2017
Mekinist Phase Tafinlar
Bay Area’s ARMO BioSciences Banks $67 Million From Big Name Investors Like Celgene (CELG) And Google (GOOG)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the successful completion of a $67 million Series C-1 private financing. The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO's lead immunotherapy agent AM0010 in non-small cell lung cancer(NSCLC) and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer.
- Source: biospace
- 527
- September 13, 2017
immunotherapy Market Views NSCLC pancreatic renal Series
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

After committing billions of dollars to a new hepatitis C cocktail that had the potential to compete with the already deeply entrenched rivals on the market, J&J is calling it quits.
- Source: endpts
- 464
- September 12, 2017
hepatitis Market Views
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT)'s Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 503
- September 12, 2017
FDA inhibitor NSCLC
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 556
- September 12, 2017
asthma Clinical Trials dupilumab Phase
FDA sends damning warning letter to Pfizer after misfiring EpiPens linked to deaths

The US Food and Drug Administration(FDA) has sent a damning warning letter to drug giant Pfizer Inc (NYSE:PFE) after it received “hundreds of complaints” that the anti-allergy EpiPen device misfired “during life-threatening emergencies”.
- Source: Proactiveinvestors
- 696
- September 11, 2017
anti-allergy FDA
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 542
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,272
- September 11, 2017
cancer Company Insight T-cell
Teleflex to take over NeoTract for $1.1bn

Teleflex has signed a definitive agreement to purchase NeoTract for approximately $1.1bn. According to the deal, Teleflex will pay $725m worth of cash upfront at closing and up to an additional $375m after the achievement of select commercial milestones associated with sales until the end of 2020.
- Source: medicaldevice-network
- 534
- September 8, 2017
aggrement invasive Market Views
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 744
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.